Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

organization that ThromboGenics intends to build.

Microplasmin - Diabetic Retinopathy: Phase II trial to evaluate microplasmin for the treatment of Diabetic Macular Edema (DME).

    - First unmasked data due to be presented at ASRS Conference in
      New York, 4 October, 2009

ThromboGenics is currently investigating microplasmin in the treatment of diabetic retinopathy, as it seeks to extend the range of indications for which the product could be potentially used. ThromboGenics completed the enrolment of a Phase II trial of microplasmin intravitreal injection for treatment of DME (MIVI II DME) in March 2009. The first unmasked data from this trial will be presented at the ASRS (American Society of Retina Specialists) Conference in New York on 4 October, 2009 by Professor Stalmans, KULeuven. This trial is designed as the initial step in evaluating the utility of microplasmin in patients with diabetes, a group which is more prone to eye disease such as diabetic retinopathy, due to their underlying medical condition.

Diabetic retinopathy is a major cause of visual loss and the leading cause of blindness in patients aged 20-60. Studies in this patient population have shown that there is a great variability in the type and level of adhesion seen between the vitreous and the retina.

TB-402 - Phase II trial assessing its long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery.

- Phase II trial proceeding well and ahead of schedule

TB-402 is a novel long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopedic surgery. The Phase II trial is proceeding well, with the first two cohorts (100 patients per cohort) of the study enrolled in just six months. We expect the third and final patient cohort to start recruiting shortly, after review
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
(Date:10/20/2014)... Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... brings Q3 orders to $5.8 million and provides a good start ... North America and one in the ... new projects at record levels," said Peter Bruijns , President ... the end of Q3 than they have been for any complete ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... OncLive® is pleased ... at Thomas Jefferson University has joined its Strategic ... Alliance Partnership program, the Sidney Kimmel Cancer Center ... awareness of the Center’s cutting-edge research programs, comprehensive ... and other health care professionals from the Sidney ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... peroxide is one of the world,s most versatile and ... O 2 is commonly used as a bleach, ... however, says Christopher J. Kiely, hydrogen peroxide has eluded ... direct, efficient and environmentally friendly means of producing it. ...
... BRISBANE, Calif., Feb. 19 InterMune, Inc. (Nasdaq: ... 7,491,794, a composition of matter patent which covers the ITMN-191 ... October 13, 2024. ITMN-191 is an inhibitor of the ... Chief Executive Officer and President of InterMune, said, "We are ...
... Inc. (Nasdaq: HGSI ) today announced that ... financial results for the year ended December 31, 2008. ... Thursday, February 26, 2009, after the capital markets close.(Logo: ... hosted by senior management and will be held on ...
Cached Biology Technology:Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide 2Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide 3Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide 4InterMune Announces Issuance of U.S. Patent for ITMN-191 2InterMune Announces Issuance of U.S. Patent for ITMN-191 3Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results 2
(Date:10/16/2014)... Northridge, Calif. (October 16, 2014) – Post-menopausal women ... effect on hormone levels or genital bleeding, after ... of an investigational fermented soy germ-based nutritional supplement ... according to a new peer-reviewed pilot study reported ... Society (NAMS) annual scientific meeting. , "These ...
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... from Philadelphia and Norway has determined the structure of an ... and is made at elevated levels in numerous forms of ... , led by researchers at The Wistar Institute, depicts the ... called NatA. Their findings, they believe, will allow them ...
... 2, 2013) In a new observational study published ... looked at the association of grape consumption, in the ... and 100% grape juice with the diet quality ... and adults. Their findings suggest that, among adults and ...
... Within sight of the Trans-Canada Highway, a team of ... set out on foot for a nearby site where they,d ... In the short distance they walked, with Canada,s ... in the Bow River bottomland, the team spotted five grizzly ...
Cached Biology News:Wistar scientists decipher structure of NatA, an enzyme complex that modifies most human proteins 2Grape consumption associated with healthier eating patterns in US children and adults 2Montana State University researchers highlight bears' use of Banff highway crossings 2Montana State University researchers highlight bears' use of Banff highway crossings 3Montana State University researchers highlight bears' use of Banff highway crossings 4